{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:02:22Z","timestamp":1780966942342,"version":"3.54.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2-3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>2,5-dimethoxy-4-methylamphetamine (DOM) is a kind of hallucinogen of phenylalkylamine. Psychedelic effects mainly include audiovisual synesthesia, complex imagery, disembodiment etc. that can impair control and cognition leading to adverse consequences such as suicide. By now, there are no specific drugs regarding the management of classic hallucinogen use clinically. We evaluated the effects of three 5-HT<jats:sub>2A<\/jats:sub> receptor antagonists ketanseirn, M100907 and olanzapine on hallucination-like behavior in therapeutic and preventive administration with male C57BL\/6J mice. Two models were used to evaluate the therapeutic potential of antagonists, one is head-twitch response (HTR) and the other is locomotion. Effects of ketanserin, M100907 and olanzapine on DOM-induced HTR were studied in preventive and therapeutic administration, respectively. In the preventive administration, the ID<jats:sub>50<\/jats:sub> values of ketanseirn, M100907 and olanzapine were 0.4 mg\/kg, 0.005 mg\/kg and 0.25 mg\/kg. In the therapeutic administration, the ID<jats:sub>50<\/jats:sub> values of ketanseirn, M100907 and olanzapine were 0.04 mg\/kg, 0.005 mg\/kg and 0.03 mg\/kg. Secondly, locomotor activity induced by DOM was performed to further evaluate the efficacy of three compounds. In locomotion, M100907(0.005 mg\/kg) whenever in preventive or therapeutic administration, reduced the increase of movement distance induced by DOM. Although ketanserin (0.4 mg\/kg) in the preventive administration also decreased the movement distance induced by DOM, it was alone administrated to influence the locomotor activity. Through HTR and locomotion, we compared the efficacy and latent side effects of ketanserin, M100907 and olanzapine against hallucinogenic like action induced by DOM. Our study provided additional experimental evidence on specific therapeutic drugs against hallucinogenic behavior induce by representative hallucinogen DOM.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000693","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T13:14:00Z","timestamp":1675862040000},"page":"92-100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Ketanserin, M100907 and Olanzapine on hallucinogenic like action induced by 2,5-dimethoxy-4-methylamphetamine"],"prefix":"10.1097","volume":"34","author":[{"given":"Kaixi","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing"},{"name":"Shihezi University College of Pharmacy\/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Shihezi, Department of Pharmacy, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shihezi University College of Pharmacy\/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Shihezi, Department of Pharmacy, Xinjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Su","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function.","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/mol.106.028720","article-title":"Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.","volume":"70","author":"Braden","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"Suppl 10","key":"R3-20250614","first-page":"28","article-title":"In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.","volume":"58","author":"Bymaster","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2013.01.007","article-title":"Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.","volume":"70","author":"Canal","year":"2013","journal-title":"Neuropharmacology"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-009-1538-z","article-title":"HTR2A A-1438G\/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.","volume":"205","author":"Chen","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R6-20250614","first-page":"123","article-title":"M-100907 (Aventis).","volume":"2","author":"de Paulis","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2011.601738","article-title":"Serotonin 2A receptor antagonists for treatment of schizophrenia.","volume":"20","author":"Ebdrup","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0025-7125(16)30780-5","article-title":"Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin.","volume":"72","author":"Frishman","year":"1988","journal-title":"Med Clin North Am"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2174\/1568026023393787","article-title":"Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists.","volume":"2","author":"Glennon","year":"2002","journal-title":"Curr Top Med Chem"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/med.2610030305","article-title":"Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents.","volume":"3","author":"Glennon","year":"1983","journal-title":"Med Res Rev"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0024-3205(79)90317-5","article-title":"Hallucinogens as a discriminative stimuli: generalization of DOM to a 5-methoxy-N, N-dimethyltryptamine stimulus.","volume":"24","author":"Glennon","year":"1979","journal-title":"Life Sci"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.","volume":"91","author":"Glennon","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/0269881110388326","article-title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.","volume":"25","author":"Halberstadt","year":"2011","journal-title":"J Psychopharmacol"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuropharm.2013.01.014","article-title":"Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.","volume":"70","author":"Halberstadt","year":"2013","journal-title":"Neuropharmacology"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1021\/jm00069a010","article-title":"Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.","volume":"36","author":"Ismaiel","year":"1993","journal-title":"J Med Chem"},{"key":"R19-20250614","first-page":"Cd006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia.","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00213-017-4610-0","article-title":"Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation.","volume":"234","author":"Kraehenmann","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.109.163451","article-title":"Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeys.","volume":"333","author":"Li","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","article-title":"Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.","volume":"722","author":"Navari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02245610","article-title":"5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats.","volume":"124","author":"Padich","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40265-020-01312-0","article-title":"Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists.","volume":"80","author":"Poyurovsky","year":"2020","journal-title":"Drugs"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00213-010-1941-5","article-title":"Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.","volume":"213","author":"Rasmussen","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(98)00019-9","article-title":"5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function.","volume":"79","author":"Roth","year":"1998","journal-title":"Pharmacol Ther"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000110410","article-title":"Association between heroin dependence and 5-HT2A receptor gene polymorphisms.","volume":"14","author":"S\u00e1iz","year":"2008","journal-title":"Eur Addict Res"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/YPG.0b013e3283050ada","article-title":"Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts.","volume":"18","author":"Saiz","year":"2008","journal-title":"Psychiatr Genet"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20174","article-title":"Novel psychoactive substances of interest for psychiatry.","volume":"14","author":"Schifano","year":"2015","journal-title":"World Psychiatry"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/BF02147960","article-title":"Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines.","volume":"20","author":"Shulgin","year":"1964","journal-title":"Experientia"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-002-1252-6","article-title":"Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+\/-)DOI] in C57BL\/6J mice.","volume":"166","author":"Smith","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1176\/ajp.125.3.357","article-title":"DOM (STP), a new hallucinogenic drug, and DOET: effects in normal subjects.","volume":"125","author":"Snyder","year":"1968","journal-title":"Am J Psychiatry"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.toxlet.2007.02.007","article-title":"5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter.","volume":"170","author":"Sogawa","year":"2007","journal-title":"Toxicol Lett"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hup.2431","article-title":"Olanzapine as the ideal \u201ctrip terminator\u201d? Analysis of online reports relating to antipsychotics\u2019 use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.","volume":"30","author":"Valeriani","year":"2015","journal-title":"Hum Psychopharmacol"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-3565(25)29259-X","article-title":"2,5-Dimethoxy-4-methylamphetamine (DOM), a neuropharmacological examination.","volume":"182","author":"Wallach","year":"1972","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:04:41Z","timestamp":1749938681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":36,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000693","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}